Embryotoxicity and maternal serum concentrations of medroxyprogesterone acetate (MPA) in baboons (Papio cynocephalus

S. Prahalada, E. Carroad, Andrew G Hendrickx

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

A single dose of MPA (Depo-Provera; Upjohn Co.; USA) was administered intramuscularly on day 27 (± 2) of gestation to three dosage groups of pregnant baboons. The dosage expressed as mg/kg corresponded to 1 (2.5 mg/kg), 10 (25 mg/kg) and 40 (100 mg/kg) times the human contraceptive dose equivalent (HDE) based on body weight. Injectable MPA was not teratogenic in baboons at 1x HDE. The teratogenicity was confined to the higher doses which included malformations of the external genitalia at 10x and 40x HDE and adrenal gland hypoplasia at 40x HDE. The maternal serum MPA concentrations were high during the critical period of adrenal and genital development. The pattern of MPA concentrations in maternal sera was similar between animals in the low dose group (10x HDE). In contrast, animals in the high dose group (40x HDE) showed interanimal variations in maternal serum concentrations of MPA. This study has demonstrated that injectable MPA is not teratogenic in baboons at human contraceptive dose equivalent and, even at higher doses, does not result in any nontarget organ malformations.

Original languageEnglish (US)
Pages (from-to)497-515
Number of pages19
JournalContraception
Volume32
Issue number5
DOIs
StatePublished - 1985

Fingerprint

Papio cynocephalus
Medroxyprogesterone Acetate
Papio
Contraceptive Agents
Mothers
Serum
Injections
Genitalia
Adrenal Glands
Body Weight
Pregnancy

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynecology

Cite this

Embryotoxicity and maternal serum concentrations of medroxyprogesterone acetate (MPA) in baboons (Papio cynocephalus. / Prahalada, S.; Carroad, E.; Hendrickx, Andrew G.

In: Contraception, Vol. 32, No. 5, 1985, p. 497-515.

Research output: Contribution to journalArticle

Prahalada, S. ; Carroad, E. ; Hendrickx, Andrew G. / Embryotoxicity and maternal serum concentrations of medroxyprogesterone acetate (MPA) in baboons (Papio cynocephalus. In: Contraception. 1985 ; Vol. 32, No. 5. pp. 497-515.
@article{059096612fd54206a33d06a881ee1d7c,
title = "Embryotoxicity and maternal serum concentrations of medroxyprogesterone acetate (MPA) in baboons (Papio cynocephalus",
abstract = "A single dose of MPA (Depo-Provera; Upjohn Co.; USA) was administered intramuscularly on day 27 (± 2) of gestation to three dosage groups of pregnant baboons. The dosage expressed as mg/kg corresponded to 1 (2.5 mg/kg), 10 (25 mg/kg) and 40 (100 mg/kg) times the human contraceptive dose equivalent (HDE) based on body weight. Injectable MPA was not teratogenic in baboons at 1x HDE. The teratogenicity was confined to the higher doses which included malformations of the external genitalia at 10x and 40x HDE and adrenal gland hypoplasia at 40x HDE. The maternal serum MPA concentrations were high during the critical period of adrenal and genital development. The pattern of MPA concentrations in maternal sera was similar between animals in the low dose group (10x HDE). In contrast, animals in the high dose group (40x HDE) showed interanimal variations in maternal serum concentrations of MPA. This study has demonstrated that injectable MPA is not teratogenic in baboons at human contraceptive dose equivalent and, even at higher doses, does not result in any nontarget organ malformations.",
author = "S. Prahalada and E. Carroad and Hendrickx, {Andrew G}",
year = "1985",
doi = "10.1016/0010-7824(85)90020-4",
language = "English (US)",
volume = "32",
pages = "497--515",
journal = "Contraception",
issn = "0010-7824",
publisher = "Elsevier USA",
number = "5",

}

TY - JOUR

T1 - Embryotoxicity and maternal serum concentrations of medroxyprogesterone acetate (MPA) in baboons (Papio cynocephalus

AU - Prahalada, S.

AU - Carroad, E.

AU - Hendrickx, Andrew G

PY - 1985

Y1 - 1985

N2 - A single dose of MPA (Depo-Provera; Upjohn Co.; USA) was administered intramuscularly on day 27 (± 2) of gestation to three dosage groups of pregnant baboons. The dosage expressed as mg/kg corresponded to 1 (2.5 mg/kg), 10 (25 mg/kg) and 40 (100 mg/kg) times the human contraceptive dose equivalent (HDE) based on body weight. Injectable MPA was not teratogenic in baboons at 1x HDE. The teratogenicity was confined to the higher doses which included malformations of the external genitalia at 10x and 40x HDE and adrenal gland hypoplasia at 40x HDE. The maternal serum MPA concentrations were high during the critical period of adrenal and genital development. The pattern of MPA concentrations in maternal sera was similar between animals in the low dose group (10x HDE). In contrast, animals in the high dose group (40x HDE) showed interanimal variations in maternal serum concentrations of MPA. This study has demonstrated that injectable MPA is not teratogenic in baboons at human contraceptive dose equivalent and, even at higher doses, does not result in any nontarget organ malformations.

AB - A single dose of MPA (Depo-Provera; Upjohn Co.; USA) was administered intramuscularly on day 27 (± 2) of gestation to three dosage groups of pregnant baboons. The dosage expressed as mg/kg corresponded to 1 (2.5 mg/kg), 10 (25 mg/kg) and 40 (100 mg/kg) times the human contraceptive dose equivalent (HDE) based on body weight. Injectable MPA was not teratogenic in baboons at 1x HDE. The teratogenicity was confined to the higher doses which included malformations of the external genitalia at 10x and 40x HDE and adrenal gland hypoplasia at 40x HDE. The maternal serum MPA concentrations were high during the critical period of adrenal and genital development. The pattern of MPA concentrations in maternal sera was similar between animals in the low dose group (10x HDE). In contrast, animals in the high dose group (40x HDE) showed interanimal variations in maternal serum concentrations of MPA. This study has demonstrated that injectable MPA is not teratogenic in baboons at human contraceptive dose equivalent and, even at higher doses, does not result in any nontarget organ malformations.

UR - http://www.scopus.com/inward/record.url?scp=0022404841&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022404841&partnerID=8YFLogxK

U2 - 10.1016/0010-7824(85)90020-4

DO - 10.1016/0010-7824(85)90020-4

M3 - Article

C2 - 2935368

AN - SCOPUS:0022404841

VL - 32

SP - 497

EP - 515

JO - Contraception

JF - Contraception

SN - 0010-7824

IS - 5

ER -